Neccessasity of Bio-imaging Hybrid Approaches Accelerating Drug Discovery Process (Mini-Review)

Imaging technologies have made a significant improvement in the past few decades and their application made a great impact on accelerating the process of drug discovery and development. The ability to non-invasively image an animal model or co-cultured live cells and validate potential drug target, biomarkers of drug efficacy and assess a pharmacological drug interaction significantly contributes to the process of translating molecules into medicines. This paper summarizes current trends in bio-imaging technologies and their application on the process of drug discovery. In particular, High Content Screening (HCS) and Virtual Screening (VS) are reviewed, and their respective examples are discussed to gain insight into state-of-the-art bio-imaging methodologies used for extracting knowledge and its application to drug discovery. This paper argues the need to reduce the gap between experimental (e.g. HCS based assays) and theoretical (e.g. VS based assays) assays. Although HCS and VS are leading drug discovery choices for the pharmaceutical industry and such investigations have been carried out in their respective campaign, the potential effects of these approaches together to facilitate the process of drug discovery has rarely been reported. Further, the prevalent research trends on developing hybrid approaches such as VS complementing HCS implies substantial enhancement to the goal of reliable drug candidate identification.

[1]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[2]  Shu-Gui Huang,et al.  Development of a High Throughput Screening Assay for Mitochondrial Membrane Potential in Living Cells , 2002, Journal of biomolecular screening.

[3]  Kai Huang,et al.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..

[4]  D. Rognan,et al.  Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.

[5]  A. Good,et al.  High-throughput and virtual screening: core lead discovery technologies move towards integration. , 2000, Drug discovery today.

[6]  J. Medina-Franco,et al.  Toward Drug Repurposing in Epigenetics: Olsalazine as a Hypomethylating Compound Active in a Cellular Context , 2014, ChemMedChem.

[7]  Ajay N. Jain Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[8]  J. Pin,et al.  Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. , 2005, Journal of medicinal chemistry.

[9]  B. Neagle,et al.  FLIPR: A New Instrument for Accurate, High Throughput Optical Screening , 1996 .

[10]  R. Aggeler,et al.  Tools to Measure Cell Health and Cytotoxicity Using High Content Imaging and Analysis. , 2018, Methods in molecular biology.

[11]  P. Liberali,et al.  Single-cell and multivariate approaches in genetic perturbation screens , 2014, Nature Reviews Genetics.

[12]  H. Groen,et al.  The prognostic value of positron emission tomography in non-small cell lung cancer: analysis of 266 cases. , 2006, Lung cancer.

[13]  João Rodrigues,et al.  Why and how have drug discovery strategies in pharma changed? What are the new mindsets? , 2016, Drug discovery today.

[14]  Yoshitomo Hamuro,et al.  Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA , 2008, Nature.

[15]  Teresa Kaserer,et al.  Prospective performance evaluation of selected common virtual screening tools. Case study: Cyclooxygenase (COX) 1 and 2 , 2015, European journal of medicinal chemistry.

[16]  Obdulia Rabal,et al.  An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries. , 2010, Molecular bioSystems.

[17]  József Nagy,et al.  Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[18]  E. Lionta,et al.  Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.

[19]  Ruben Abagyan,et al.  Novel cGMP efflux inhibitors identified by virtual ligand screening (VLS) and confirmed by experimental studies. , 2012, Journal of medicinal chemistry.

[20]  M. Raichle,et al.  Subgenual prefrontal cortex abnormalities in mood disorders , 1997, Nature.

[21]  W. Drevets,et al.  The Subgenual Anterior Cingulate Cortex in Mood Disorders , 2008, CNS Spectrums.

[22]  Gang Liu,et al.  Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. , 2003, Journal of the American Chemical Society.

[23]  H. Remmer,et al.  The role of the liver in drug metabolism , 1970 .

[24]  Campbell McInnes,et al.  Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.

[25]  J. Wendoloski,et al.  Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. , 2004, Journal of medicinal chemistry.

[26]  Yasuyoshi Watanabe,et al.  [Molecular imaging for drug development]. , 2007, Brain and nerve = Shinkei kenkyu no shinpo.

[27]  F. Totzke,et al.  Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization. , 2009, Bioorganic & medicinal chemistry.

[28]  S. Perry,et al.  Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. , 2011, BioTechniques.

[29]  E. Kantrowitz,et al.  A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. , 2009, Bioorganic & medicinal chemistry.

[30]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[31]  Wolfgang Link,et al.  High content screening: seeing is believing. , 2010, Trends in biotechnology.

[32]  Thomas Blaschke,et al.  The rise of deep learning in drug discovery. , 2018, Drug discovery today.

[33]  R. Weissleder,et al.  Molecular imaging in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[34]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[35]  G. Klebe,et al.  Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.

[36]  S. Danti,et al.  Poly(vinyl alcohol)/gelatin Hydrogels Cultured with HepG2 Cells as a 3D Model of Hepatocellular Carcinoma: A Morphological Study , 2015, Journal of functional biomaterials.

[37]  Kiran Boppana,et al.  Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models. , 2009, European journal of medicinal chemistry.

[38]  Nadine H. Elowe,et al.  Experimental Screening of Dihydrofolate Reductase Yields a “Test Set” of 50,000 Small Molecules for a Computational Data-Mining and Docking Competition , 2005, Journal of biomolecular screening.

[39]  Sissades Tongsima,et al.  Pre-docking filter for protein and ligand 3D structures , 2008, Bioinformation.

[40]  Vladimir Poroikov,et al.  Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource , 2014, Chemistry of Heterocyclic Compounds.

[41]  D. Schuster,et al.  Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists. , 2016, European journal of medicinal chemistry.

[42]  Jeffrey W. Peng,et al.  Theory and applications of NMR-based screening in pharmaceutical research. , 2004, Chemical reviews.

[43]  Robert Nadon,et al.  Systematic error detection in experimental high-throughput screening , 2011, BMC Bioinformatics.

[44]  Emilio Bombardieri,et al.  The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  Jean-Pierre Gotteland,et al.  Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. , 2005, Journal of medicinal chemistry.

[46]  Wei-liang Zhu,et al.  Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets , 2009, Acta Pharmacologica Sinica.

[47]  William Thomsen,et al.  Functional assays for screening GPCR targets. , 2005, Current opinion in biotechnology.